FDA Asked to Approve Darzalex Triple Combo for Relapsed or Refractory Multiple Myeloma
Janssen has asked the U.S. Food and Drug Administration (FDA) to allow Darzalex (daratumumab) to also be used in combination with Kyprolis (carfilzomib)…
Ana Pena, PhD, — 
Articles by Ana Pena
Bone Marrow Macrophages Could Predict Resistance to Velcade, Study Suggests
The multiple myeloma therapy Velcade (bortezomib) can induce the formation of pro-inflammatory macrophages — a kind of white blood cell — that promote the growth of myeloma tumors, Israeli researchers found. The presence of such cells in the bone marrow could help explain why some myelomas…
Tally of Risk Factors Can Identify Myeloma Patients at Risk of Deep-vein Blood Clots, Study Suggests
A simple score of risk factors could help alert doctors to a likelihood of dangerous blood clots, called venous thromboembolism, forming as a side effect of immunomodulatory therapies (IMiD) for multiple myeloma. Researchers established the set of factors — based on a person’s age, race, and medical…
CAR T-Cell Candidate bb2121 Shows Promise in Heavily Pre-treated Myeloma, Interim Data Show
The candidate CAR-T cell therapy bb2121 showed a favorable safety profile and eliminated traces of cancer in nearly half of heavily pre-treated multiple myeloma patients included in a Phase 1 clinical trial, interim results show.
Pivotal OPTIMISMM Trial Shows Benefits of Pomalyst Triple Combo Therapy
Treatment with Pomalyst (pomalidomide) in combination with Velcade (bortezomib) and dexamethasone prolongs survival without disease worsening in patients with multiple myeloma who have failed prior treatments, including Revlimid (lenalidomide), results from a pivotal clinical trial show. Building on this…
Revlimid and Imnovid Triple Combos Approved in EU for Adults with Multiple Myeloma
The European Commission has approved two combination therapies based on Celgene‘s Revlimid (lenalidomide) and Imnovid (pomalidomide), added to Velcade (bortezomib) and dexamethasone, for the treatment of some adult patients with multiple myeloma. Revlimid, combined with Velcade and dexamethasone (RVd), is now indicated for…
Investigational Ygalo Shows Promise for Relapsed or Refractory Multiple Myeloma, Interim Data Show
Ygalo (melflufen), a novel compound under investigation for relapsed and refractory multiple myeloma, was well-tolerated and demonstrated promising signs of high efficacy in two global clinical trials conducted by Oncopeptides. The data was…
Kyprolis Combo Yields Positive Results as Initial Treatment for Multiple Myeloma
A combination of Kyprolis (carfilzomib) and dexamethasone, already approved for relapsed and refractory multiple myeloma, may also be effective and safe as a first-line treatment for newly diagnosed patients, according to a study. The dual combo yielded the…
FDA Grants Poseida’s P-BCMA-101 RMAT Status for Treatment of Multiple Myeloma
The U.S. Food and Drug Administration (FDA) has granted P-BCMA-101, Poseida Therapeutics’ CAR T-cell therapy and lead product candidate, the Regenerative Medicine Advanced Therapy (RMAT) designation for the treatment of relapsed or refractory…
New Compound Safely Halts Advanced Myeloma Progression in Small Pilot Study
A new investigational compound targeting a central pathway in cancer development showed promising results in patients with relapsed or refractory multiple myeloma in a small Phase 1/2a pilot trial. The agent was able to trigger myeloma cell death and halt cancer progression in two out…